The analysts have spoken so it must be so. Shire is a no brainer takeover candidate and it is only a matter of time for some Big Pharma to gobble her up. GSK and Pfizer, with their big cash reserves and announced forays into rare disease areas, would seem to be leadign suspects to make a move.
Shire is deemed attractive as a supplier of niche product to the ADHD market and to various rare disease applications. It's differentiated. It's profitable. It has a pipeline. It has said that it expects to grow by 15% annually through 2015. What's not to like?
Shire CEO Angus Russell says, "We're an independent company, but we're a public company as well, and on behalf of our shareholders obviously we always have to entertain approaches that are significantly value-enhancing." See Fierce Biotech.
Make me an offer our shareholders can't refuse. It's only a matter of time as it is so lovely in the Shire.
Posted by Bruce Lehr May 13th 2011.